The CD47-SIRPα Immune Checkpoint
Immunity, vol. 52, pp. 742–752
Authors 3
-
The Netherlands Cancer Institute
Affiliation as printed
Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands
-
Leiden University Medical Center
Affiliation as printed
Department of Medical Oncology, Leiden University Medical Center (LUMC), Leiden, the Netherlands
-
Leiden University Medical Center · The Netherlands Cancer Institute
Affiliation as printed
Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: t.schumacher@nki.nl
Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden, the Netherlands
Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands
Cited by 696 stored of 781
Cited by patents worldwide 6 (Lens.org)
-
IMMUNE CELL INHIBITION BY IMMUNE CHECKPOINT ENGAGERSEP4507727A4 2026-04-08 Pending
-
DOSE REGIMENS FOR THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTATWO2025224169A1 2025-10-30 Pending
-
CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTATWO2024256618A1 2024-12-19 Pending
-
PHENYLPIPERIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEINWO2024188734A1 2024-09-19 Pending
-
PHENYLPIPERIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEINWO2024133014A1 2024-06-27 Pending